Cargando…
The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo
Influenza A virus (IAV) is a common pathogen of respiratory disease. The IAV-induced seasonal epidemics and the sporadic pandemics are associated with high morbidity and mortality. Therefore, effective protection and therapy for IAV infections is an important challenge in countering this public heal...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455256/ https://www.ncbi.nlm.nih.gov/pubmed/30866762 http://dx.doi.org/10.1080/22221751.2018.1559709 |
_version_ | 1783409673658957824 |
---|---|
author | Schloer, Sebastian Goretzko, Jonas Kühnl, Alexander Brunotte, Linda Ludwig, Stephan Rescher, Ursula |
author_facet | Schloer, Sebastian Goretzko, Jonas Kühnl, Alexander Brunotte, Linda Ludwig, Stephan Rescher, Ursula |
author_sort | Schloer, Sebastian |
collection | PubMed |
description | Influenza A virus (IAV) is a common pathogen of respiratory disease. The IAV-induced seasonal epidemics and the sporadic pandemics are associated with high morbidity and mortality. Therefore, effective protection and therapy for IAV infections is an important challenge in countering this public health threat. Because vaccinations only protect against known circulating strains, and the currently available antivirals pose the risk of resistance formation, drugs targeting host cell factors needed for viral replication offer a promising therapeutic approach. In this study, we describe the use of the antifungal therapeutics posaconazole and itraconazole in the therapy of IAV. We show that both drugs efficiently inhibit the propagation of IAV in the cell culture model without being cytotoxic. The mode of action is probably based on several targets and includes both a priming of the interferon response and the induced imbalance of cellular cholesterol. The antiviral effect of itraconazole could be confirmed in the mouse model, where the administration of itraconazole led to a drastic reduction in mortality and a significant increase in the survival rate. Thus, our data indicate a promising therapeutic potential of at least itraconazole in influenza therapy. |
format | Online Article Text |
id | pubmed-6455256 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-64552562019-04-18 The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo Schloer, Sebastian Goretzko, Jonas Kühnl, Alexander Brunotte, Linda Ludwig, Stephan Rescher, Ursula Emerg Microbes Infect Article Influenza A virus (IAV) is a common pathogen of respiratory disease. The IAV-induced seasonal epidemics and the sporadic pandemics are associated with high morbidity and mortality. Therefore, effective protection and therapy for IAV infections is an important challenge in countering this public health threat. Because vaccinations only protect against known circulating strains, and the currently available antivirals pose the risk of resistance formation, drugs targeting host cell factors needed for viral replication offer a promising therapeutic approach. In this study, we describe the use of the antifungal therapeutics posaconazole and itraconazole in the therapy of IAV. We show that both drugs efficiently inhibit the propagation of IAV in the cell culture model without being cytotoxic. The mode of action is probably based on several targets and includes both a priming of the interferon response and the induced imbalance of cellular cholesterol. The antiviral effect of itraconazole could be confirmed in the mouse model, where the administration of itraconazole led to a drastic reduction in mortality and a significant increase in the survival rate. Thus, our data indicate a promising therapeutic potential of at least itraconazole in influenza therapy. Taylor & Francis 2019-01-16 /pmc/articles/PMC6455256/ /pubmed/30866762 http://dx.doi.org/10.1080/22221751.2018.1559709 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Schloer, Sebastian Goretzko, Jonas Kühnl, Alexander Brunotte, Linda Ludwig, Stephan Rescher, Ursula The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo |
title | The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo |
title_full | The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo |
title_fullStr | The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo |
title_full_unstemmed | The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo |
title_short | The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo |
title_sort | clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455256/ https://www.ncbi.nlm.nih.gov/pubmed/30866762 http://dx.doi.org/10.1080/22221751.2018.1559709 |
work_keys_str_mv | AT schloersebastian theclinicallylicensedantifungaldrugitraconazoleinhibitsinfluenzavirusinvitroandinvivo AT goretzkojonas theclinicallylicensedantifungaldrugitraconazoleinhibitsinfluenzavirusinvitroandinvivo AT kuhnlalexander theclinicallylicensedantifungaldrugitraconazoleinhibitsinfluenzavirusinvitroandinvivo AT brunottelinda theclinicallylicensedantifungaldrugitraconazoleinhibitsinfluenzavirusinvitroandinvivo AT ludwigstephan theclinicallylicensedantifungaldrugitraconazoleinhibitsinfluenzavirusinvitroandinvivo AT rescherursula theclinicallylicensedantifungaldrugitraconazoleinhibitsinfluenzavirusinvitroandinvivo AT schloersebastian clinicallylicensedantifungaldrugitraconazoleinhibitsinfluenzavirusinvitroandinvivo AT goretzkojonas clinicallylicensedantifungaldrugitraconazoleinhibitsinfluenzavirusinvitroandinvivo AT kuhnlalexander clinicallylicensedantifungaldrugitraconazoleinhibitsinfluenzavirusinvitroandinvivo AT brunottelinda clinicallylicensedantifungaldrugitraconazoleinhibitsinfluenzavirusinvitroandinvivo AT ludwigstephan clinicallylicensedantifungaldrugitraconazoleinhibitsinfluenzavirusinvitroandinvivo AT rescherursula clinicallylicensedantifungaldrugitraconazoleinhibitsinfluenzavirusinvitroandinvivo |